✦ LIBER ✦

Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants

✍ Scribed by Maria Debiec-Rychter; Jan Cools; Herlinde Dumez; Raf Sciot; Michel Stul; Nicole Mentens; Hilde Vranckx; Bartosz Wasag; Hans Prenen; Johannes Roesel; Anne Hagemeijer; Allan Van Oosterom; Peter Marynen

Book ID: 119758245
Publisher: Elsevier Science
Year: 2005
Tongue: English
Weight: 416 KB
Volume: 128
Category: Article
ISSN: 0016-5085
DOI: 10.1053/j.gastro.2004.11.020

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Mechanisms of resistance to imatinib and

Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor

✍ Wei-Lien Wang; Anthony Conley; David Reynoso; Laura Nolden; Alexander J. Lazar; 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 384 KB

A Review of Resistance Patterns and Phen

A Review of Resistance Patterns and Phenotypic Changes in Gastrointestinal Stromal Tumors Following Imatinib Mesylate Therapy

✍ Kai Bickenbach; Rebecca Wilcox; Jula Veerapong; Hedy Lee Kindler; Mitchell C. Po 📂 Article 📅 2007 🏛 Springer-Verlag 🌐 English ⚖ 410 KB

563 POSTER In vitro activity of the mult

563 POSTER In vitro activity of the multi-targeted kinase inhibitor sorafenib (BAY43-9006) against gastrointestinal stromal tumor (GIST) mutants refractory to imatinib mesylate

✍ H. Prenen; B. Dewaele; J. Cools; N. Mentens; C. Stefan; R. Sciot; P. Schöffski; 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 61 KB

571 KitLow Interstitial Cell of Cajal St

571 KitLow Interstitial Cell of Cajal Stem Cells are a Cause of Resistance to Imatinib Mesylate in Gastrointestinal Stromal Tumors

✍ Michael R. Bardsley; Yujiro Hayashi; David T. Asuzu; Gianrico Farrugia; Brian P. 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 50 KB

Nilotinib in the treatment of advanced g

Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib

✍ M. Montemurro; P. Schöffski; P. Reichardt; H. Gelderblom; J. Schütte; J.T. Hartm 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 156 KB

Efficacy and safety of motesanib, an ora

Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors

✍ Robert S. Benjamin; Patrick Schöffski; Jörg Thomas Hartmann; Allan Van Oosterom; 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 438 KB